¼¼°èÀÇ RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ÄÄÆ÷³ÍÆ®º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Ä¡·á ¿µ¿ªº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2024-2030³â)
Real World Evidence Solutions Market Size, Share & Trends Analysis Report By Component, By Application, By End-use, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1493334
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,194,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,571,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,325,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÇÁ¦ ¼¼°è Áõ°Å ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ½ÇÁ¦ ¼¼°è Áõ°Å ¼Ö·ç¼Ç ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 8.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇßÀ¸¸ç 2030³â±îÁö 46¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ¿©·¯ ºÐ¾ß¿¡¼­ RWEÀÇ Àû¿ë È®´ë, À¯¸®ÇÑ Á¤ºÎ ±ÔÁ¦, ±â¼ú Áøº¸, ¾ç ±â¹Ý¿¡¼­ °¡Ä¡ ±â¹Ý °ü¸®·ÎÀÇ Àüȯ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¶Á÷¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2024³â 3¿ù, DARWIN EU(Data Analysis & Real World Interrogation Network)´Â ¿¬°£ »õ·Î¿î 10°³ÀÇ µ¥ÀÌÅÍ ÆÄÆ®³Ê¸¦ Ãß°¡Çϰí RWD ¿¬±¸ ´É·ÂÀ» °­È­ÇÒ °èȹÀ» ¹ßÇ¥Çß½À´Ï´Ù. DARWIN EU´Â À¯·´ 13°³±¹¿¡ °ÉÃÄ 20°³ ±â°üÀ¸·Î ±¸¼ºµÈ ³×Æ®¿öÅ©·Î, º´¿ø, 1Â÷ ÀÇ·á½Ã¼³, °Ç°­º¸Çè µ¥ÀÌÅͺ£À̽º, µî·Ï, ¹ÙÀÌ¿À¹ðÅ© µî ´Ù¾çÇÑ Ãâó¿¡¼­ RWE¸¦ µµÃâÇϱâ À§ÇØ °ø°ø±â°ü°ú ¹Î°£´Üü¿Í Çù·ÂÇϰí ÀÖ½À´Ï´Ù.

ÀÌ RWE´Â EMA ¹× EU Àü¿ªÀÇ ±¹°¡ ±ÔÁ¦ ´ç±¹ÀÇ ±ÔÁ¦ Ȱµ¿À» Áö¿øÇÕ´Ï´Ù. DARWIN EU´Â À¯·´ Àü¿ªÀÇ ¾à 1¾ï 3,000¸¸ ¸íÀÇ È¯ÀڷκÎÅÍ ¾òÀº µ¥ÀÌÅ͸¦ Ȱ¿ëÇϰí RWD ¿¬±¸¸¦ ÅëÇØ È®½ÇÇÑ Áõ°Å¸¦ Á¦°øÇϰíÀÚ ÇÕ´Ï´Ù. ÁÖ¸ñÇÒ Á¡Àº ÀÌ ³×Æ®¿öÅ©°¡ °øÅë µ¥ÀÌÅÍ ¸ðµ¨À» äÅÃÇÏ°í µ¥ÀÌÅÍ ºÐ¼®À» Ç¥ÁØÈ­ÇÏ´Â ÇÑÆí, µ¥ÀÌÅÍ ÆÄÆ®³Ê¿¡ ÀÇÇÑ ·ÎÄÃÀÇ º¸Á¸°ú ÇØ¼®À» ÅëÇØ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ È®º¸Çϰí ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº µ¥ÀÌÅÍ º¸È£¸¦ ¼±È£ÇÏ°í ´ë±Ô¸ð ¸ÖƼ µ¥ÀÌÅͺ£À̽º ¿¬±¸ÀÇ È¿À²ÀûÀÎ ±¸ÇöÀ» ÃËÁøÇÕ´Ï´Ù.

¶ÇÇÑ RWEÀÇ ÁÖ¿ä ¼ÒºñÀÚ´Â Á¦¾à ±â¾÷ ¹× ÀÇ·á±â±â ±â¾÷ÀÔ´Ï´Ù. Á¦Ç° ¼ö¸íÁÖ±â Àüü¿¡ °ÉÃÄ °¡Ä¡¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ±×°ÍÀº »ý¸í °úÇÐ ¿¬±¸, ÀÓ»ó½ÃÇè ¹× ¿¬±¸, ½ÃÆÇ ÈÄ Á¶»ç ¹× ±ÔÁ¦ ¿ä±¸ »çÇ׿¡ °ÉÃÄ »ç¿ëµË´Ï´Ù. »ý¸í °úÇÐ ¿¬±¸¿¡¼­ RWE´Â ¿¬±¸ÀÚ°¡ ÀáÀçÀûÀΠȯÀÚ¸¦ ½Äº°Çϰí ÀÓ»ó½ÃÇèÀ»À§ÇÑ ÀûÀýÇÑ ÅëÇÕ ±âÁØÀ» ÀÛ¼ºÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÔÀ¸·Î½á ½ÃÇè Àü ¿¬±¸ ¼³°è¿¡ Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇ衤¿¬±¸¿¡ À־´Â º¸´Ù ±¤¹üÀ§ÇÑ »çȸÃþ¿¡ °üÇÑ Á¤º¸¸¦ Á¦°øÇØ, ȯÀÚ º¸°í °á°ú Á¶»ç µîÀÇ Á¾·¡ÀÇ °á°ú ÁöÇ¥¸¦ º¸¿ÏÇÏ´Â °ÍÀ¸·Î, Á¾·¡ÀÇ ÀÓ»ó½ÃÇèÀÇ ÇѰ踦 ±Øº¹Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

°Ô´Ù°¡, ÀÇ·á Á¦Ç° ¼³°èÀÚ´Â Çõ½ÅÀûÀÌ°í »õ·Î¿î Ä¡·á Á¢±Ù¹ýÀ» âÃâÇϱâ À§ÇØ RWD¿Í RWE¸¦ »ç¿ëÇÏ¿© ÀÓ»ó½ÃÇè ¼³°è(¿¹: ½Ç¿ëÀû ÀÓ»ó½ÃÇè, ´ë±Ô¸ð ´Ü¼ø ½ÃÇè) ¹× °üÂû ¿¬±¸¸¦ Áö¿øÇÕ´Ï´Ù. µû¶ó¼­ ±â¼úÀº ÀÇ·á ÀÇ»ç °áÁ¤¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù, Johnson & JohnsonÀº ÇÁ·Î½ºÆåƼºê °üÂû ·¹Áö½ºÆ®¸® ¿¬±¸ÀÇ °á°ú, Åõ½Ã ºÒÇÊ¿äÇÑ ½ÉÀå ¼ÒÀÛ ÀåÄ¡ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

¶ÇÇÑ, ½Å°æ ºÐ¾ß¿¡¼­´Â RWE¸¦ °­È­Çϱâ À§ÇØ RWD ¼öÁý¿¡ ÁÖ·ÂÇÏ´Â ¿©·¯ ±â¾÷ÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, OM1Àº 2023³â 9¿ù Mental Health and Neuroscience RWD Network È®ÀåÀÇ ÀÏȯÀ¸·Î ÆÄŲ½¼º´(PD)¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ µî±Þ µ¥ÀÌÅÍ ¼¼Æ®¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ µ¥ÀÌÅͼ¼Æ®´Â OM1 Real-World Data Cloud¿¡ ÀÖ´Â 70¸¸ ¸íÀÇ PD ȯÀÚÀÇ µ¥ÀÌÅÍ¿Í ÇÔ²² ½Å°æ°ú Àǻ簡 ±àÁ¤ÀûÀ¸·Î ÃßÀûÇÑ 7,000¸í ÀÌ»óÀÇ PD ȯÀÚÀÇ ÇÁ¸®¹Ì¾ö µ¥ÀÌÅ͸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ÀÌ Á¾ÇÕÀûÀÎ µ¥ÀÌÅͷκÎÅÍ ¾òÀº RWEÀÇ Áö½ÄÀº PD Paysent JourneyÀÇ ÀÌÇØ¸¦ ±í°Ô Çϰí Äɾî¿Í °á°úÀÇ °³¼±À¸·Î À̾îÁú °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÇÁ¦ ¼¼°è Áõ°Å ¼Ö·ç¼Ç ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Real World Evidence(RWE) ¼Ö·ç¼Ç: COVID-19ÀÇ ¿µÇâ

Á¦5Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå : ÄÄÆ÷³ÍÆ® ºÐ¼®

Á¦6Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå : ¿ëµµ ºÐ¼®

Á¦7Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºÐ¼®

Á¦8Àå RWE(Real World Evidence) ¼Ö·ç¼Ç ½ÃÀå : Ä¡·á ¿µ¿ª ºÐ¼®

Á¦9Àå RWE(Real World Evidence)(RWE) ¼Ö·ç¼Ç ½ÃÀå :Áö¿ª ½ÃÀå ºÐ¼®, ÄÄÆ÷³ÍÆ®º°, ¿ëµµº°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)

Á¦10Àå °æÀï ºÐ¼®

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦12Àå Àü·«Àû ±ÇÀå »çÇ×°ú ÅëÂû

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Real World Evidence Solutions Market Growth & Trends:

The global real world evidence solutions market size is expected to reach USD 4.6 billion by 2030, registering a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Key driving factors of the market include growing applications of RWE in several fields, favorable government regulations, technological advancements, and a shift from volume to value-based care. Furthermore, a growing number of strategic initiatives by organizations are anticipated to positively influence market growth.

In March 2024, DARWIN EU, the Data Analysis & Real World Interrogation Network, announced plans to enhance its capacity for RWD studies by adding 10 new data partners within the year. With a network of 20 institutions spanning 13 European countries, DARWIN EU collaborates with public & private entities to derive RWE from diverse sources, including hospitals, primary care facilities, health insurance databases, registries, and biobanks.

This RWE supports regulatory activities of the EMA and national regulators across the EU. Leveraging data from approximately 130 million patients across Europe, DARWIN EU aims to deliver robust evidence through RWD studies. Notably, the network employs a common data model to standardize data interpretation while ensuring data privacy through local storage and analysis by data partners. This approach prioritizes data protection and facilitates the efficient execution of large-scale, multi-database studies.

Furthermore, major consumers of RWE are pharmaceutical and medical device companies. This is because it can provide value across the entire product lifecycle. It has applications across life science research, clinical trials & studies, post-market surveillance, and regulatory requirements. In life science research, RWE can inform pretrial study design by assisting researchers in identifying potential patients and creating proper inclusion criteria for clinical trials. Within clinical trials & studies, it helps overcome traditional clinical trials' limitations by providing information about a broader cross-section of society and supplementing traditional outcome measures, such as patient-reported outcome surveys.

Moreover, medical product designers are using RWD & RWE to aid clinical trial designing (e.g., pragmatic clinical trials, large simple trials) and observational studies to produce innovative, new treatment approaches. Thus, technology plays a significant role in healthcare decisions, which, in turn, promotes segment growth. For instance, in July 2023, Johnson & Johnson gained approval for certain cardiac ablation devices for fluoroscopy-free use following a prospective observational registry study-an instance of the agency employing RWE in device reviews.

In addition, several companies are focusing on RWD collection to enhance RWE in the neurology sector. For instance, in September 2023, OM1 announced a curated research-grade dataset focused on Parkinson's disease (PD) as part of its Mental Health and Neuroscience RWD Network expansion. This dataset features premium data from over 7,000 individuals with PD, tracked prospectively by neurologists, along with data from 700,000 PD patients in the OM1 Real-World Data Cloud. The RWE insights from this comprehensive data are anticipated to enhance understanding of PD patient journeys, leading to improved care & outcomes.

Real World Evidence Solutions Market Report Highlights:

Table of Contents

Chapter 1 Research Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Real World Evidence (Rwe) Solutions Market Variables Trends & Scope

Chapter 4 Real World Evidence (Rwe) Solutions: COVID-19 Impact

Chapter 5 Real World Evidence Solutions Market: Component Analysis

Chapter 6 Real World Evidence Solutions Market: Application Analysis

Chapter 7 Real World Evidence Solutions Market: End Use Analysis

Chapter 8 Real World Evidence Solutions Market: Therapeutic Area Analysis

Chapter 9 Real World Evidence (Rwe) Solutions Market: Regional Market Analysis, By Component, Application, Therapeutic Area, And End Use 2018 - 2030 (USD Million)

Chapter 10 Competitive Analysis

Chapter 11 Company Profiles

Chapter 12 Strategic Recommendation And Insights

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â